Standard

Would You Use it With a seal of approval? important attributes of 2,4-Dinitrophenol (2,4-DnP) as a hypothetical Pharmaceutical Product. / Bleasdale, Emma; Thrower, Sam; Petroczi, Andrea.

In: FRONTIERS IN PSYCHIATRY, Vol. 9, 20.04.2018.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Bleasdale, Emma; Thrower, Sam; Petroczi, Andrea / Would You Use it With a seal of approval? important attributes of 2,4-Dinitrophenol (2,4-DnP) as a hypothetical Pharmaceutical Product.

In: FRONTIERS IN PSYCHIATRY, Vol. 9, 20.04.2018.

Research output: Contribution to journalArticle

BibTeX

@article{30a164426e7e4ad89db78cb760c392c1,
title = "Would You Use it With a seal of approval? important attributes of 2,4-Dinitrophenol (2,4-DnP) as a hypothetical Pharmaceutical Product",
abstract = "Background: 2,4-Dinitrophenol (2,4-DNP) is an effective but highly dangerous fatburner, not licensed for human consumption. Death cases reported for 2,4-DNPoverdose, particularly among young adults, have raised concerns about the ineffectiveregulatory control, lack of education and risks associated with impurity, and the unknown concentration of 2,4-DNP purchased on the Internet.Methods: Using a sequential mixed method design and based on a hypothetical scenario as if 2,4-DNP was a licensed pharmaceutical drug, first we conducted a qualitative study to explore what product attributes people consider when buying a weight-loss aid. Focus group interviews with six females and three males (mean age = 21.6 ± 1.8 years) were audiorecorded, transcribed verbatim, and subjected to thematic analysis. Sixteen attributes were identified for the Best–Worst Scale (BWS) in the quantitative survey with 106 participants (64% female, mean age = 27.1 ± 11.9 years), focusing on 2,4-DNP. Demographics, weight satisfaction, and risk for eating disorder data were collected.Results: In contrast to experienced users such as bodybuilders, our study participantsapproached 2,4-DNP cautiously. Attributes of 2,4-DNP as a hypothetical weight-lossdrug comprised a range of desirable and avoidable features. Of the 16 selected attributes, BWS suggested that long-term side effects were the most and branding was the least important attribute. Effectiveness and short-term side effects were also essential. Those in the >25 year group showed least concerns for legality. Neutral BWS scores for cost, treatment, degree of lifestyle changes required, and specificity required for the hypothetical weight-loss drug to be effective were likely caused by disagreement about their importance among the participants, not indifference.Conclusion: With advances in research, 2,4-DNP as a pharmaceutical drug in the future for treating neurodegenerative diseases and potentially for weight loss is not inconceivable. Caution is warranted for interpreting the BWS scores. Owing to the difference in what data represent at individual vs. population levels, with pooled data, the method correctly identifies attributes by which most people are satisfied but misrepresents attributes that are individually very important but not universally agreed. Whilst this may be an advantage in marketing applications, it limits the utility of BWS as a research tool.© 2018 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See http://creativecommons.org/licenses/by/4.0/",
keywords = "diet pill, fat burner, 2-4-dinitrophenol, DNP, weight loss, bodybuilding, eating disorder",
author = "Emma Bleasdale and Sam Thrower and Andrea Petroczi",
year = "2018",
month = "4",
doi = "10.3389/fpsyt.2018.00124",
volume = "9",
journal = "FRONTIERS IN PSYCHIATRY",
issn = "1664-0640",
publisher = "Frontiers Media",

}

RIS

TY - JOUR

T1 - Would You Use it With a seal of approval? important attributes of 2,4-Dinitrophenol (2,4-DnP) as a hypothetical Pharmaceutical Product

AU - Bleasdale,Emma

AU - Thrower,Sam

AU - Petroczi,Andrea

PY - 2018/4/20

Y1 - 2018/4/20

N2 - Background: 2,4-Dinitrophenol (2,4-DNP) is an effective but highly dangerous fatburner, not licensed for human consumption. Death cases reported for 2,4-DNPoverdose, particularly among young adults, have raised concerns about the ineffectiveregulatory control, lack of education and risks associated with impurity, and the unknown concentration of 2,4-DNP purchased on the Internet.Methods: Using a sequential mixed method design and based on a hypothetical scenario as if 2,4-DNP was a licensed pharmaceutical drug, first we conducted a qualitative study to explore what product attributes people consider when buying a weight-loss aid. Focus group interviews with six females and three males (mean age = 21.6 ± 1.8 years) were audiorecorded, transcribed verbatim, and subjected to thematic analysis. Sixteen attributes were identified for the Best–Worst Scale (BWS) in the quantitative survey with 106 participants (64% female, mean age = 27.1 ± 11.9 years), focusing on 2,4-DNP. Demographics, weight satisfaction, and risk for eating disorder data were collected.Results: In contrast to experienced users such as bodybuilders, our study participantsapproached 2,4-DNP cautiously. Attributes of 2,4-DNP as a hypothetical weight-lossdrug comprised a range of desirable and avoidable features. Of the 16 selected attributes, BWS suggested that long-term side effects were the most and branding was the least important attribute. Effectiveness and short-term side effects were also essential. Those in the >25 year group showed least concerns for legality. Neutral BWS scores for cost, treatment, degree of lifestyle changes required, and specificity required for the hypothetical weight-loss drug to be effective were likely caused by disagreement about their importance among the participants, not indifference.Conclusion: With advances in research, 2,4-DNP as a pharmaceutical drug in the future for treating neurodegenerative diseases and potentially for weight loss is not inconceivable. Caution is warranted for interpreting the BWS scores. Owing to the difference in what data represent at individual vs. population levels, with pooled data, the method correctly identifies attributes by which most people are satisfied but misrepresents attributes that are individually very important but not universally agreed. Whilst this may be an advantage in marketing applications, it limits the utility of BWS as a research tool.© 2018 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See http://creativecommons.org/licenses/by/4.0/

AB - Background: 2,4-Dinitrophenol (2,4-DNP) is an effective but highly dangerous fatburner, not licensed for human consumption. Death cases reported for 2,4-DNPoverdose, particularly among young adults, have raised concerns about the ineffectiveregulatory control, lack of education and risks associated with impurity, and the unknown concentration of 2,4-DNP purchased on the Internet.Methods: Using a sequential mixed method design and based on a hypothetical scenario as if 2,4-DNP was a licensed pharmaceutical drug, first we conducted a qualitative study to explore what product attributes people consider when buying a weight-loss aid. Focus group interviews with six females and three males (mean age = 21.6 ± 1.8 years) were audiorecorded, transcribed verbatim, and subjected to thematic analysis. Sixteen attributes were identified for the Best–Worst Scale (BWS) in the quantitative survey with 106 participants (64% female, mean age = 27.1 ± 11.9 years), focusing on 2,4-DNP. Demographics, weight satisfaction, and risk for eating disorder data were collected.Results: In contrast to experienced users such as bodybuilders, our study participantsapproached 2,4-DNP cautiously. Attributes of 2,4-DNP as a hypothetical weight-lossdrug comprised a range of desirable and avoidable features. Of the 16 selected attributes, BWS suggested that long-term side effects were the most and branding was the least important attribute. Effectiveness and short-term side effects were also essential. Those in the >25 year group showed least concerns for legality. Neutral BWS scores for cost, treatment, degree of lifestyle changes required, and specificity required for the hypothetical weight-loss drug to be effective were likely caused by disagreement about their importance among the participants, not indifference.Conclusion: With advances in research, 2,4-DNP as a pharmaceutical drug in the future for treating neurodegenerative diseases and potentially for weight loss is not inconceivable. Caution is warranted for interpreting the BWS scores. Owing to the difference in what data represent at individual vs. population levels, with pooled data, the method correctly identifies attributes by which most people are satisfied but misrepresents attributes that are individually very important but not universally agreed. Whilst this may be an advantage in marketing applications, it limits the utility of BWS as a research tool.© 2018 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See http://creativecommons.org/licenses/by/4.0/

KW - diet pill

KW - fat burner

KW - 2-4-dinitrophenol

KW - DNP

KW - weight loss

KW - bodybuilding

KW - eating disorder

U2 - 10.3389/fpsyt.2018.00124

DO - 10.3389/fpsyt.2018.00124

M3 - Article

VL - 9

JO - FRONTIERS IN PSYCHIATRY

T2 - FRONTIERS IN PSYCHIATRY

JF - FRONTIERS IN PSYCHIATRY

SN - 1664-0640

ER -

ID: 997531